TET2 defects, either mutations or deletions, were discovered in 17 of 90 patients with MDS (19%), in 24 of 198 patients with MPN (12%), and in 5 of 21 patients with secondary AML (24%) [50]. The gene discussed is TET2; the disease is myeloproliferative disorder.